Sacituzumab tirumotecan
2870-009
Phase 3 mab active
Quick answer
Sacituzumab tirumotecan for Non-small Cell Lung Cancer (NSCLC) is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Modality
- mab
- Status
- active